FEATURED COMPANIES
- Applikon Biotechnology BV
- bbi-biotech GmbH
- Danaher Corporation
- Eppendorf AG
- Esco Group of Companies
- Merck KGaA
Key Questions Answered in this Report:
- What is the importance of biomanufacturing in the medical field? How the biomanufacturing market is proceeding toward next-generation biomanufacturing?
- What are the key trends of the global next-generation biomanufacturing market? How is the market evolving and what is its future scope?
- What are the major drivers, challenges, and opportunities of the global next-generation biomanufacturing market?
- What are the key developmental strategies implemented by the key players of the global next-generation biomanufacturing to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
- What is the regulatory scenario of the global next-generation biomanufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of next-generation biomanufacturing products?
- What was the market size of the global next-generation biomanufacturing market in 2018 and what is the market size anticipated to be in 2029? What is the expected growth rate of the global next-generation biomanufacturing market during the period between 2019 and 2029?
- What are the different next-generation biomanufacturing products used in the medical field? Which product type dominated the market in 2018 and why? Which product type is expected to witness the highest growth rate and to dominate in the market in 2029?
- What are the different medical application areas of the global next-generation biomanufacturing market? Which application type dominated the market in 2018 and is expected to dominate in 2029?
- What are the different end users associated with next-generation biomanufacturing? What was the contribution of each user type in the global next-generation biomanufacturing market in 2018 and what is it expected to be in 2029?
- What were the market values of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2018 and what are the values expected to be in 2019? What are the different macro and micro factors influencing the growth of the market?
- Which region is expected to contribute the highest sales in the global next-generation biomanufacturing market during the period between 2018 and 2029? Which region and country carries the potential for the significant expansion of key companies for different next-generation biomanufacturing products? What are the leading countries of different regions that contribute significantly toward the growth of the next-generation biomanufacturing market?
- What are the key players of the global next-generation biomanufacturing market and what is their role in the market?
Overview of the Global Next-Generation Biomanufacturing Market
The rapid maturation of the biopharmaceutical sector denotes the increasing importance of biomanufacturing as the most basic procedure for the development and manufacture of biologic-based products. With increasing commercialization of biopharmaceuticals and the addition of more products in the development pipeline, biopharmaceutical companies are looking forward to adopting novel biomanufacturing strategies with an increased focus on balancing innovation in process design, performance, and efficiency with speed and cost. The need for advanced biomanufacturing practices in order to meet the demand of the growing patient population has paved the way for the development of next-generation biomanufacturing products. Next-generation biomanufacturing products are designed to provide seamless services that are superior in terms of both quality and efficiency as compared to first-generation products. Increased funding from private investors and the government for the development of next-generation biomanufacturing facilities promoting rapid technological advancement in biomanufacturing products is one of the most prominent factors driving the growth of the next-generation biomanufacturing market. One of the major trends of the next-generation biomanufacturing market is the shifting focus toward the adoption of single-use products, such as single-use bioreactors and single-use biocontainers. This is mainly attributed to the huge number of benefits associated with single-use products, with regard to cost savings, reduced risk of product contamination, and increased flexibility in multi-product facilities. With more companies entering the next-generation biomanufacturing market through product innovations, several novel next-generation biomanufacturing products are expected to come up, actively driving the growth of the market in the upcoming years.
The Global Next-Generation Biomanufacturing Market Report projects the market to grow at a significant CAGR of 10% during the forecast period, 2019-2029.
Expert Quote
“The leading contributors in the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.”
Scope of the Global Next-Generation Biomanufacturing Market
The report constitutes an in-depth study of the global next-generation biomanufacturing market, including a thorough analysis of the types of products. The study also presents a detailed analysis of the market dynamics and the estimation of the market size over the forecast period 2019-2029. The scope of this report is focused on the different products, workflow, application areas, end users associated with the global next-generation biomanufacturing market, as well as the country-wise analysis.
The purpose of the study is to gain a holistic view of the global next-generation biomanufacturing market in terms of various factors influencing it, including regulatory reforms and technological advancements. The market has been segmented on the basis of ‘product type’, ‘workflow’, ‘medical application’, ‘end-user’, and ‘region’. The scope of this report is centered upon conducting a detailed study of the products allied with the global next-generation biomanufacturing market. In addition, the study also includes exhaustive information on the unmet needs, new products, competitive landscape, market share of leading manufacturers, the growth potential of each product, workflow, application, end-user, and region, as well as other vital information with respect to the global next-generation biomanufacturing market.
Market Segmentation
By Workflow and Product
- Continuous Upstream Biomanufacturing
- Bioreactors/Fermenters
- Cell Culture Products
- Filtration Systems
- Bags & Containers
- Mixing System
- Sterilizers
- Biosafety Cabinets
- Incubators
- Other Instruments and Accessories
- Single-Use Upstream Biomanufacturing
- Single-Use Bioreactors
- Single-Use Bags and Containers
- Single-Use Tubing and Connectors
- Single-Use Mixing Systems
- Single-Use Sensors and Probes
- Downstream Biomanufacturing
- Chromatography Systems
- Filtration Systems
- Membrane Absorbers
- Instruments and Accessories
- Single-Use Equipment and Accessories
By Medical Application
- Monoclonal Antibodies
- Hormones
- Vaccines
- Recombinant Proteins
- Others
By End User
- Commercial Stage
- Biopharmaceutical Companies
- CMOs/CDMOs
- Preclinical and Development Stage
- Biopharmaceutical Companies
- CMOs/CDMOs
- Research Institutions
By Region
- North America
- Europe
- Latin America
- Middle-East and Africa
Key Companies of the Global Next-Generation Biomanufacturing Industry
The key players contributing to the global next-generation biomanufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, bbi-biotech GmbH, Esco Group of Companies, Pierre Guérin, Solaris Biotechnology Srl., PBS Biotech, Inc., ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and Shanghai Bailun Biotechnology Co. Ltd.
Enterprise License customers will receive an Excel spreadsheet containing additional data.
FEATURED COMPANIES
- Applikon Biotechnology BV
- bbi-biotech GmbH
- Danaher Corporation
- Eppendorf AG
- Esco Group of Companies
- Merck KGaA
Executive Summary1 Product Definition
LOADING...
FEATURED COMPANIES
- Applikon Biotechnology BV
- bbi-biotech GmbH
- Danaher Corporation
- Eppendorf AG
- Esco Group of Companies
- Merck KGaA
According to the market intelligence report titled “Global Next-Generation Biomanufacturing Market - Analysis and Forecast, 2019-2029”, the global next-generation biomanufacturing market was valued at $14.80 billion in 2018 and is expected to be $42.78 billion in 2029. The next-generation biomanufacturing market is expected to grow at a lower double-digit compounded annual growth rate in the forecast period 2019-2029. The growth is aided primarily by the technological advancements in the field of biomanufacturing and increased funding from private investors and government for the development and expansion of next-generation biomanufacturing facilities to meet the growing demand for biopharmaceuticals.
With the changing healthcare needs globally, the biopharmaceutical market is increasingly gaining prominence by bringing out novel biologic-based medicines to treat the growing patient population. Increasing the prevalence of diseases has put enormous pressure on the biopharmaceutical sector to propel the production of novel therapeutics in a cost-effective way. Among the different biopharmaceuticals available in the market, the demand for biologics and biosimilars are considerably high. Manufacturing these biologic-based drugs and bringing them to the market entails an increased focus on the safety, purity, potency, identity, and stability of the product, thereby balancing innovation in process design, performance, and efficiency with speed and cost. The fast growth of the global biopharmaceutical market has therefore prompted enormous research activities in the biomanufacturing sector to boost the production of these medicines. Currently, the biomanufacturing sector is witnessing immense technological innovations impacting upstream and downstream bioprocessing of biologic-based medicines. In addition to pharmaceutical companies, several contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) are also investing significantly to expand their biopharmaceutical production capacity and introducing emerging alternative technologies that are contributing significantly toward the growth of the next-generation biomanufacturing market. With the main goal to produce products that are superior to first-generation products, the next-generation biomanufacturing market remains an area of high attractiveness with a lot of investment happening from both the public and private sectors. Several new companies are also entering the market and trying to gain significant market share through product innovations and are aligning their strategies to sustain the market competition. Collaborations, partnerships, joint-ventures, mergers, and acquisitions are some of the common business development strategies adopted by key companies of the global next-generation biomanufacturing market.
According to Abdul Wahid, Principal Analyst, “By workflow, upstream biomanufacturing led the market in 2018 with bioreactors being its major contributor. In 2018, bioreactors/fermentors accounted for approximately 20.20% of the market share of the continuous upstream biomanufacturing market. However, shifting focus toward the adoption of single-use systems is one of the major key trends of the global next-generation biomanufacturing market”
Research Highlights:
The leading contributors to the global next-generation biomanufacturing market predominantly prefer partnerships and alliances to sustain the market competition and strengthen their business position. Most of the market leaders are collaborating with technology-based startups to gain their expertise in technology.
Monoclonal antibody product segment with relatively high market approval rates is dominating the next-generation biomanufacturing market, by the medical application. Monoclonal antibodies segment was valued at $6.66 billion in 2018, contributing to 45% of the total market share in 2018.
In terms of end-users, commercial-stage end-user dominated the global next-generation biomanufacturing market and was valued at $11.39 billion in 2018. On the other hand, for both commercial-stage end-users and preclinical and development stage end users, biopharmaceutical companies were the major contributor of revenue, followed by CMOs/CDMOs.
Among the different regions, North America leads the global next-generation biomanufacturing market in 2018, with the U.S. being the major contributor to revenue. In 2018, North America contributed 35.40% of the total market share and the U.S. alone contributed to more than 95.40% of its market share.
This market intelligence report provides a multidimensional view of the global next-generation biomanufacturing market in terms of market size and growth potential. This research report aims at answering various aspects of the global next-generation biomanufacturing market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as product launches, partnerships, and product approvals, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers and trend analysis by segment and by region.
This report is a meticulous compilation of research on more than 10 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants and vendors. The report also profiles 15 companies including several key players, such as Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, GEA Group Aktiengesellschaft, bbi-biotech GmbH, Esco Group of Companies, Pierre Guérin, Solaris Biotechnology Srl., PBS Biotech, Inc., ZETA GmbH, Applikon Biotechnology BV, Meissner Filtration Products, Inc., and Shanghai Bailun Biotechnology Co. Ltd.
The answers to the following key questions can be derived from this report:
- What is the importance of biomanufacturing in the medical field? How the biomanufacturing market is proceeding toward next-generation biomanufacturing?
- What are the key trends of the global next-generation biomanufacturing market? How is the market evolving and what is its future scope?
- What are the major drivers, challenges, and opportunities of the global next-generation biomanufacturing market?
- What are the key developmental strategies implemented by the key players of the global next-generation biomanufacturing to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
- What is the regulatory scenario of the global next-generation biomanufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of next-generation biomanufacturing products?
- What was the market size of the global next-generation biomanufacturing market in 2018 and what is the market size anticipated to be in 2029? What is the expected growth rate of the global next-generation biomanufacturing market during the period between 2019 and 2029?
- What are the different next-generation biomanufacturing products used in the medical field? Which product type dominated the market in 2018 and why? Which product type is expected to witness the highest growth rate and to dominate the market in 2029?
- What are the different medical application areas of the global next-generation biomanufacturing market? Which application type dominated the market in 2018 and is expected to dominate in 2029?
- What are the different end users associated with next-generation biomanufacturing? What was the contribution of each user type in the global next-generation biomanufacturing market in 2018 and what is it expected to be in 2029?
- What were the market values of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2018 and what are the values expected to be in 2029? What are the different macro and micro factors influencing the growth of the market?
- Which region is expected to contribute the highest sales in the global next-generation biomanufacturing market during the period between 2018 and 2029? Which region and country carries the potential for the significant expansion of key companies for different next-generation biomanufacturing products? What are the leading countries of different regions that contribute significantly toward the growth of the next-generation biomanufacturing market?
- What are the key players of the global next-generation biomanufacturing market and what is their role in the market?
- Applikon Biotechnology BV
- bbi-biotech GmbH
- Danaher Corporation
- Eppendorf AG
- Esco Group of Companies
- GEA Group Aktiengesellschaft
- Meissner Filtration Products, Inc.
- Merck KGaA
- PBS Biotech, Inc.
- Pierre Guérin
- Sartorius AG
- Shanghai Bailun Biotechnology Co. Ltd.
- Solaris Biotechnology Srl.
- Thermo Fisher Scientific Inc.
- ZETA GmbH
